Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Chemoradiotherapy for Recurrent Esophageal Cancer
NCT04404491Phase 3Unknown
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 3 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Henan University of Science and Technology. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04404491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404491.